The structure of insulin  Red: carbon; green: oxygen; blue: nitrogen; pink: sulfur. The blue/purple ribbons denote the skeleton [-N-C-C-]n in the protein's amino acid sequence H-[-NH-CHR-CO-]n-OH where R is the part protruding from the skeleton in each amino acid.The primary structure of insulin i.e. amino acid sequence1. Preproinsulin (Leader, B chain, C chain, A chain); proinsulin consists of BCA, without L2. Spontaneous folding3. A and B chains linked by sulphide bonds4. Leader and C chain are cut off5. Insulin molecule remains
Find information on thousands of medical conditions and prescription drugs.

Apidra

Insulin (from Latin insula, "island", as it is produced in the Islets of Langerhans in the pancreas) is a polypeptide hormone that regulates carbohydrate metabolism. Apart from being the primary effector in carbohydrate homeostasis, it also has a substantial effect on small vessel muscle tone, controls storage and release of fat (triglycerides) and cellular uptake of both amino acids and some electrolytes. In this last sense, it has anabolic properties. Its concentration (more or less, presence or absence) has extremely widespread effects throughout the body. more...

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Insulin is used medically in some forms of diabetes mellitus. Patients with type 1 diabetes mellitus depend on exogenous insulin (injected subcutaneously) for their survival because of an absolute deficiency of the hormone; patients with type 2 diabetes mellitus have either relatively low insulin production or insulin resistance or both, and a non-trivial fraction of type 2 diabetics eventually require insulin administration when other medications become inadequate in controlling blood glucose levels.

Insulin has the empirical formula C257H383N65O77S6.

Insulin structure varies slightly between species of animal. Its carbohydrate metabolism regulatory function strength in humans also varies. Pig insulin is particularly close to the human one.

Discovery and characterization

In 1869 Paul Langerhans, a medical student in Berlin, was studying the structure of the pancreas under a microscope when he noticed some previously-unidentified cells scattered in the exocrine tissue. The function of the "little heaps of cells," later known as the Islets of Langerhans, was unknown, but Edouard Laguesse later argued that they may produce a secretion that plays a regulatory role in digestion.

In 1889, the Polish-German physician Oscar Minkowski in collaboration with Joseph von Mehring removed the pancreas from a healthy dog to demonstrate this assumed role in digestion. Several days after the dog's pancreas was removed, Minkowski's animal keeper noticed a swarm of flies feeding on the dog's urine. On testing the urine they found that there was sugar in the dog's urine, demonstrating for the first time the relationship between the pancreas and diabetes. In 1901, another major step was taken by Eugene Opie, when he clearly established the link between the Islets of Langerhans and diabetes: Diabetes mellitus.... is caused by destruction of the islets of Langerhans and occurs only when these bodies are in part or wholly destroyed. Before this demonstration, the link between the pancreas and diabetes was clear, but not the specific role of the islets.

Over the next two decades, several attempts were made to isolate the secretion of the islets as a potential treatment. In 1906 Georg Ludwig Zuelzer was partially successful treating dogs with pancreatic extract, but unable to continue his work. Between 1911 and 1912, E.L. Scott at the University of Chicago used aqueous pancreatic extracts and noted a slight diminution of glycosuria, but was unable to convince his director and the research was shut down. Israel Kleiner demonstrated similar effects at Rockefeller University in 1919, but his work was interrupted by World War I and he was unable to return to it. Nicolae Paulescu, a professor of physiology at the Romanian School of Medicine, published similar work in 1921 that was carried out in France and patented in Romania, and it has been argued ever since by Romanians that he is the rightful discoverer.

Read more at Wikipedia.org


[List your site here Free!]


Research and Markets: Non-Invasive Insulins Expected to Address Key Unmet Need in Diabetes Market
From Business Wire, 11/23/04

DUBLIN, Ireland -- Research and Markets has announced the addition of The Diabetes Market Outlook: Market analysis of future growth and leading players by sector to their offering

Type 2 diabetes has now hit epidemic levels, and is expected to increase further over the coming years with the rise in the age demographic and the escalation in rates of obesity. Currently, The insulin market is dominated by three companies - Eli Lilly, Novo Nordisk and Sanofi-Aventis - but the OAD market is more diverse and more valuable, thus representing more opportunities for entry. This study found that non-invasive insulins will address the key unmet need in the diabetes market. Several pills, inhalers, mouth sprays and patches are in development and this is likely to cause an increase in the number of users in the type 2 patient population currently put off by subcutaneous injections. Also, Dual PPAR agonists have blockbuster potential because they can treat both diabetes and heart disease.

This new report analyzes diabetes market dynamics and provides a country-by-country brand analysis. This report focuses on key anti-diabetic drugs and reviews the growth strategies of leading players. Upcoming revolutionary products in development are also investigated, highlighting those expected to drive market growth and transform treatment options for diabetic patients.

This report provides:

--Value and growth breakdowns of the insulin market and all sub-sections of OADs from 2002 - 2003. The report also includes a sales breakdown by country, highlighting differences in usage of TZDs in the US and European sectors.

--Strategic analysis of all major diabetes drugs, such as Actos, Avandia, Humalog, NovoLin and Lantus, as well as newly approved therapies Levemir and Apidra.

--An examination of the key trends which are currently affecting the market such as the increasing use of insulin and combination therapies amongst type 2 diabetics.

--An in-depth analysis of the future growth drivers in the market, such as development of non-invasive insulins, PPAR agonists and GLP-1 agonists.

--Company analysis and market shares of insulin and OAD markets in the US and Europe, including Eli Lilly, Novo Nordisk, Sanofi-Aventis, Takeda, GSK and BMS.

--Comprehensive review of the major companies' R&D portfolios.

Questions answered by this report include:

--Which sectors of the diabetes market are currently driving growth?

--Why is insulin being increasingly prescribed for type 2 diabetic patients?

--Which products in development will drive future growth?

--Which products are at risk from genericization in the coming years?

--How can the lifecycle of diabetes drugs be managed and extended?

--Who are the key players in the insulin and OAD markets?

--How are companies shaping themselves to become the diabetes leaders of tomorrow?

Chapters provided include:

--Epidemiology analysis

--Global diabetes market analysis

--Insulin market analysis

--Oral antidiabetic (OAD) market

--Leading players in the diabetes

Eli Lilly

Novo Nordisk

Takeda

GlaxoSmithKline

Bristol-Myers Squibb

Pfizer

Novartis

Merck KGaA

For more information visit http://www.researchandmarkets.com/reports/c9933

COPYRIGHT 2004 Business Wire
COPYRIGHT 2004 Gale Group

Return to Apidra
Home Contact Resources Exchange Links ebay